US2004180896A1PendingUtilityA1

P38 inhibitors and methods of use thereof

55
Priority: Mar 3, 2003Filed: Oct 15, 2003Published: Sep 16, 2004
Est. expiryMar 3, 2023(expired)· nominal 20-yr term from priority
A61P 43/00A61P 37/02A61P 9/00A61P 37/06A61P 37/00A61P 35/00A61P 31/00A61P 29/00A61P 25/28A61P 31/12A61P 25/04A61P 31/04A61P 25/18A61P 25/00A61P 19/10A61P 1/04A61P 17/06A61P 19/08A61P 19/00A61P 19/02C07D 401/14C07D 403/04C07D 471/04C07D 413/12C07D 261/20C07D 231/56C07D 403/12C07D 405/12A61K 31/437C07D 401/04
55
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of various disorders mediated by p38.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A compound including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, said compound having the Formula:  
       
         
           
           
               
               
           
         
       
       where 
 Y is CR 1 , O, S, or NR 2 ;  
 W is CR 3 , N, or NR4, provided that W is NR 4 , S, or O when Y is CR 1  and W is CR 3  or  
 N when Y is NR 2 ; 
 R 3  is H, NH 2 , F, Cl, methyl or substituted methyl;  
 R 4  is H, methyl or substituted methyl;  
 R 1  and R 2  are independently H, OH, an amine protecting group, Z n -NR a R b , Z n —NR a (C═O)R b , Z n -SO 2 R a , Z n -SOR a , Z n -SR a , Z n -OR a , Z n -(C═O)R a , Z n —(C═O)OR a , Z n -O—(C═O)R a , alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 1 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl, and Z n -Ar 1  may be substituted or unsubstituted;  
 Ar 1  is aryl or heteroaryl, each of which may be substituted or unsubstituted;  
 R a  and R b  are independently H, OH, an amine protecting group, an alcohol protecting group, an acid protecting group, a sulfur protecting group, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 1 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl, and Z n -Ar 1  may be substituted or unsubstituted,  
 or R a  and R b  together with the atoms to which they are both attached form a saturated or partially unsaturated heterocycle ring having 1 or more heteroatoms in said ring, wherein said heterocycle may be substituted or unsubstituted and wherein said heterocycle may be fused to an aromatic ring;  
 Z is alkylene having from 1 to 4 carbons, or alkenylene or alkynylene each having from 2 to 4 carbons, wherein said alkylene, alkenylene, or alkynylene may be substituted or unsubstituted;  
 n is 0 or 1;  
 
 U is CR c  or N;  
 V is CR c  or N; 
 R c  is H, F, Cl, methyl or substituted methyl;  
 
 X is O, S, SO, SO 2 , NR 5 , C═O, CH 2 , CH 2 Z n -OH, or C═NOR d ; 
 R 5  is H, methyl, or substituted methyl;  
 R d  is H, PO 3 H 2 , SO 3 H 2 , alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 1 , said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl and Z n -Ar 1  may be substituted or unsubstituted;  
 
 G, H, J, and T independently are N or CR z , provided that when any of said G, H, J, and T are N the total number of G, H, J, or T that is N does not exceed 2; 
 R z  is H, F, Cl, Br, CF 3 , OR 6 , SR 6 , lower alkyl (C 1 -C 4 ), CN, or NR 6 R 7 ;  
 R 6  and R 7  are independently H, CF 3 , lower alkyl (C 1 -C 4 ) or lower heteroalkyl (C 1 -C 4 );  
 
 Q is —NR 8 CONH—, —NHCO—, —NR 8 SO 2 NH—, —NHSO 2 —, —CONR 11 —; 
 R 8  is H or lower (C 1 -C 4 ) alkyl;  
 R 11  is H or lower (C 1 -C 4 ) alkyl;  
 
 R x  is CR 9 R 10 ) m —, —O(CR 9 R 10 ) m —, NH(CR 9 R 10 ) m —, or —S(CR 9 R 10 ) m — provided that Q is —CONR 11 — when R x  is —O(CR 9 R 10 ) m —, —NH(CR 9 R 10 ) m —, or —S(CR 9 R 10 ) m —; 
 R 9  and R 10  are independently H, or lower alkyl, or R 9  and R 10  together with the atoms to which they are both attached form a cycloalkyl ring which may be saturated or partially unsaturated;  
 m is 1-3;  
 
 R y  is H, PO 3 H, an amine protecting group, an oxygen protecting group, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 2 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -Ar 2  and Z n -heterocycloalkyl may be substituted or unsubstituted; 
 Ar2 is aryl or heteroaryl, each of which may be substituted or unsubstituted, wherein said substitution can be 1-3 substituents independently selected from F, Cl, Br, CF 3 , CN, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, —OR 12 , —SR 12 , —SO 2 R 12 , —SO 2 NR 13 R 12 , NR 13 SO 2 R 12 , Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 1 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl and Z n -Ar 1  may be substituted or unsubstituted;  
 R 12  and R 13  are independently H, alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 1 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl and Z n -Ar 1  may be substituted or unsubstituted;  
 wherein when Ar 2  is substituted with —SO 2 NR 13 R 12 , R 12  and R 13  can form a cycloalkyl ring or heterocycloalkyl ring that may be substituted or unsubstituted wherein said substitution can be substituents selected from alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, —COR 12 , —SO 2 R 12 , Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 1 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl and Z n -Ar 1  may be substituted or unsubstituted;  
 wherein when Q is —CONR 11 , R y  in combination with R 11  is additionally cycloalkyl ring or heterocycloalkyl ring that may be substituted or unsubstituted with groups selected from alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, Z n -Ar 1 , —COR 14 , or —SO 2 R 14 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl, Z n -Ar 1 , —COR 14 , and —SO 2 R 14  may be substituted or unsubstituted; and 
 R 14  is alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, Z n -cycloalkyl wherein said cycloalkyl is saturated or partially unsaturated, Z n -heterocycloalkyl wherein said heterocycloalkyl is saturated or partially unsaturated, or Z n -Ar 1 , wherein said alkyl, allyl, alkenyl, alkynyl, heteroalkyl, heteroallyl, heteroalkenyl, heteroalkynyl, alkoxy, heteroalkoxy, Z n -cycloalkyl, Z n -heterocycloalkyl, and Z n -Ar 1  may be substituted or unsubstituted.  
 
 
 
     
     
         3 . The compound of  claim 1 , wherein W is CH 2  and Y is NR 2 .  
     
     
         4 . The compound of  claim 1 , wherein G, J, K and T are CR z .  
     
     
         5 . The compound of  claim 1 , wherein X is NH, S, or O.  
     
     
         6 . The compound of  claim 1 , wherein R x  is CH 2  and Q is —NHCO—.  
     
     
         7 . The compound of  claim 6 , wherein R y  isopropyl or  
       
         
           
           
               
               
           
         
       
     
     
         8 . The compound of  claim 1 , wherein R x  is CH 2  and Q is —NR 8 CONH—.  
     
     
         9 . The compound of  claim 8 , wherein R y  is  
       
         
           
           
               
               
           
         
       
     
     
         10 . A composition comprising a compound of  claim 1  and a pharmaceutically acceptable carrier.  
     
     
         11 . A method of treating or preventing a p38-mediated condition in a human or animal, comprising administering to said human or animal a compound of  claim 1  in an amount effective to treat or prevent said p38-mediated condition or a pharmaceutical composition comprising said compound.  
     
     
         12 . The method of  claim 11 , wherein said p38-mediated condition is inflammatory disease, autoimmune disease, destructive bone disorder, proliferative disorder, infectious disease, viral disease, or neurodegenerative disease.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.